期刊
ANNALS OF THE RHEUMATIC DISEASES
卷 73, 期 2, 页码 385-390出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2012-202589
关键词
-
类别
资金
- National Institute of Arthritis and Musculoskeletal and Skin Diseases [P60-AR047785]
- Arthritis Foundation
- American College of Rheumatology Research and Education Fund
- Takeda Pharmaceuticals USA, Inc.
Objective To examine the association between cardioprotective use of low-dose aspirin and the risk of recurrent gout attacks among gout patients. Methods We conducted an online case-crossover study of individuals with gout over 1 year. The following information was obtained during gout attacks: the onset dates, symptoms and signs, medications, and exposure to potential risk factors, including daily aspirin use and dosage, during the 2-day hazard period prior to the gout attacks. The same exposure information was also obtained over 2-day control periods. Results Of the 724 participants analysed, 40.5% took aspirin <= 325 mg/day during either a hazard or a control period. Compared with no aspirin use, the adjusted OR of gout attacks increased by 81% (OR=1.81, 95% CI 1.30 to 2.51) for <= 325 mg/day of aspirin use on two consecutive days. The corresponding ORs were stronger with lower doses (eg, OR=1.91 for <= 100 mg, 95% CI 1.32 to 2.85). These associations persisted across subgroups by sex, age, body mass index categories and renal insufficiency status. Concomitant use of allopurinol nullified the detrimental effect of aspirin. Conclusions Our findings suggest that the use of low-dose aspirin on two consecutive days is associated with an increased risk of recurrent gout attacks. Recommended serum urate monitoring with concomitant use and dose adjustment of a urate-lowering therapy among patients with gout may be especially important to help avoid the risk of gout attacks associated with low-dose aspirin.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据